drugset
drugset / Trial / NCT04296578

Study Evaluating Sodium Selenite in Combination With Abiraterone in Castrate Resistant Prostate Cancer Progressing on Abiraterone

NCT04296578 ↗

Phase 1 Withdrawn Stanford University
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to access the safety of combining sodium selenite with abiraterone and to see what doses of sodium selenite can be safely combined with abiraterone in treating castration resistant prostate cancer.

Timeline

Start
2020-10
Primary completion
2022-10
Completion
2023-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Abiraterone acetate Small molecule 1000 mg Oral
Subject sodium selenite Unknown 5.5 mg Oral
Subject sodium selenite Unknown 11 mg Oral
Subject sodium selenite Unknown 16.5 mg Oral
Subject sodium selenite Unknown 22 mg Oral
Subject sodium selenite Unknown 27.5 mg Oral
Subject sodium selenite Unknown 33 mg Oral
Background Prednisone Other / unclassified 5 mg Oral

Indications

castration-resistant prostate carcinoma